In combination with the ATR inhibitor AZD6738, BOLD-100 exhibited synergistic effects in vitro and enhanced anti-tumor activity in vivo, significantly suppressing tumor growth in a Capan-1 xenograft model. The gene discussed is ATR; the disease is neoplasm.